HC Wainwright reiterated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research report released on Thursday morning,Benzinga reports. HC Wainwright currently ...

Eleva, a German biopharmaceutical company, and 3PBIOVIAN, a global contract development and manufacturing organization (CDMO), have announced a strategic partnership to enhance the production of Eleva ...

which along with PNH and IgAN include atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathy (C3G), and idiopathic membranous nephropathy (IMN). It still has a long way to go to reach that ...

Eleva, a pioneer in unlocking biologics based on a breakthrough manufacturing platform, and 3PBIOVIAN, a contract development ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nineteen analysts that are covering the firm, Ratings reports. Eight research ...

A Bradford Grammar School (BGS) pupil is leading a challenge to raise funds for a kidney research charity in honour of his younger brother - with more than £7,500 donated to the cause so far.

which along with PNH and IgAN include atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathy (C3G), and idiopathic membranous nephropathy (IMN). IgAN is a key focus for Novartis ...

Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, and 3PBIOVIAN, a leading contract development and manufacturing organization (CDMO), ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

An FDA advisory committee panel is scheduled to discuss the merits of Novartis’ oral factor B inhibitor Fabhalta in the rare kidney disease C3 glomerulopathy (C3G). The Cardiovascular and Renal ...

Piper Sandler adjusted its stance on Q32 Bio Inc. (NASDAQ: QTTB), downgrading the biotech firm's stock rating from Overweight to Neutral and significantly reducing the price target to $4.00 from the ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...